Biogen BIIB
NASDAQ BIIB
$250.69 -3.15 (-1.24%)
At close: Oct 23, 2026 · 4:00 PM EDT

Biogen (BIIB) Land & Improvements (2009 - 2010)

Updated

Biogen (BIIB) recorded Land & Improvements of $107.6 million in Q4 2010, down 3.2% from $111.2 million a year earlier.

Analysis

Biogen (BIIB) Land & Improvements (2009 - 2010) Analysis & Trends

  • Across earlier years, Land & Improvements came in at $111.2 million in FY2009.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Land & Improvements (Qtr)
1 Eli Lilly 1,137.66 Bn 1,106.24 Bn 19.71 Bn -
2 Johnson & Johnson 636.13 Bn 556.00 Bn 17.30 Bn -
3 AbbVie 505.28 Bn 478.39 Bn 12.70 Bn -
4 Merck 358.10 Bn 312.48 Bn 12.21 Bn -
5 Novartis Ag 292.59 Bn 256.58 Bn 11.24 Bn -
6 Astrazeneca 265.81 Bn 239.50 Bn 12.86 Bn -
7 Amgen 237.53 Bn 192.93 Bn 7.24 Bn -
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn -
9 Pfizer 171.17 Bn 117.82 Bn 10.94 Bn -
10 Biogen 36.99 Bn 23.65 Bn 1.96 Bn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2010 107.60 Mn
Dec 31, 2009 111.20 Mn
API Access

Biogen Land & Improvements API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=land-and-improvements&ticker=BIIB&period=max&api_key=YOUR_API_KEY